Table 3 Literature review of the survival of pLCNEC patients
Author | Year | Cases | Age | Sex (M/F) | Smoking rate (%) | Country/region (institutions) | 5-year survival | Median OS | Stage | Potential prognostic factors |
|---|---|---|---|---|---|---|---|---|---|---|
Casali et al. [6] | 2004 | 33 | 63.5 | 31/2 | 95 | Italy (SI) | 51% | Na | I–IIIA | C-kit protein expression |
Doddoli et al. [7] | 2004 | 20 | 62 | 18/2 | 85.0 | France (SI) | 36% | 49 | ALL | None (due to small number of patients) |
Veronesi et al. [8] | 2006 | 144 | 63 | 117/27 | 94 | Italy (MI) | 42.5% | Na | I–III | Age, stage III, pneumonectomy |
Ryuge et al. [9] | 2012 | 30 | 67 | 27/3 | 93.3 | Japan (SI) | 47% | 28.4 | I–III | Nestin expression |
Fournel et al. [10] | 2013 | 63 | 64 | 49/14 | 88.8 | France (SI) | 49.2% | Na | ALL | pT stage |
Zhang et al. [11] | 2015 | 50 | 59 | 47/3 | 70 | China (SI) | 58% | 49.3 (DFS) | I–III | Serum Alb and NSE levels |
Eichhorn et al. [5] | 2015 | 57 | 62.4 | 41/16 | 94.7 | Germany (SI) | 50% (3-yr) | 36 | ALL | pN stage, expression of CD56 and chromogranin-A |
Roesel et al. [12] | 2016 | 127 | 63.8 | 82/45 | 97.6 | Germany (SI) | 53.8% | Na | All | pT and pN stages |
Kim et al. [13] | 2017 | 139 | 64 | 126/13 | 83.5 | Korea (SI) | 53% | Na | all | Adjuvant treatment (for stage II or higher) |
Okui et al. [14] | 2017 | 26 | 68.8 | 23/3 | 96.2 | Japan (SI) | Stage I: 86.7% stage > I: 45.5% | 54.4 | I–IIIA | NLR, pathological stages |
Filosso et al. [15] | 2017 | 400 | 66 | 252/148 | 24.8 | ESTS (MI) | 45% | 43 | all | Age, performance status, TNM stage, adjuvant chemotherapy |
Eichhorn et al. [16] | 2018 | 76 | 60.9 | 54/22 | 97.0 | Germany (SI) | 29% | Na | all | Pathological N stage, PD-L1 expression |
Zhou et al. [17] | 2018 | 126 | 64 | 118/8 | 57.1 | China (SI) | 50.4% (3-year) | 44.5 | All | Tumour location, EGFR mutation |
Ohtaki et al. [18] | 2018 | 95 | 74 | 82/13 | 94.8 | Japan (MI) | 51.6% | 40 | All | Pleural invasion, Foxp3 expression |
Cattoni et al. [19] | 2019 | 72 | 65 | 43/29 | 96 | Italy and USA (MI) | 57.6% | Na | I–IIIA | Tumour size > 3 cm |
Roesel et al. [20] | 2020 | 251 | 64 | 156/95 | 88.4 | Germany (MI) | 38.8 | NA | All | Age, pN stage, chemotherapy |
Shi et al. [21] | 2020 | 106 | 65.6 | 105/5 | 51.4 | China (SI) | 36% | 24.1 | All | pT stage, NLR |